Conclusion: Our results support a revision of the NeuPSIG recommendations for the pharmacotherapy of neuropathic pain. Inadequate response to drug treatments constitutes a substantial unmet need in patients with neuropathic pain. Modest efficacy, large placebo responses, heterogeneous diagnostic criteria, and poor phenotypic profiling probably account for moderate trial outcomes and should be taken into account in future studies.
PubMed 25575710 ↗Gabapentin
Also known as Neurontin
The short answer. Most people who report on Gabapentin say it did not help (only 39% of 81 positive). It is most often used for anxiety: 80% of 44 reports say that improved. It is well studied — 532 meta-analyses on PubMed. The most common complaint is withdrawal.
From 145 mentions in total — the rest didn't say how it went and aren't counted.
What Gabapentin does, according to users
Of the people who reported each effect, the share who said it got better.
1 more with fewer than 3 reports
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 532 meta-analyses on PubMed ↗ · 672 randomized trials ↗
Conclusion: (CGRP(r)mAbs) have the best safety and efficacy profile of all drugs for migraine prophylaxis, followed closely by gepants.
PubMed 37208596 ↗Conclusion: The only HT regimens that showed significantly greater efficacy than fezolinetant 45 mg on any of the outcomes analyzed are not available in the United States. Fezolinetant 45 mg once daily was statistically significantly more effective than other non-HTs in reducing the frequency of moderate to severe VMS.
PubMed 38016166 ↗Conclusion: High-level evidence related to pharmacological strategies for managing Lewy body dementia is rare. Strategies for important areas of need in Lewy body dementia, such as autonomic symptoms and caregiver burden, have not been investigated, nor have the views of patients and caregivers about pharmacological strategies.
PubMed 26085043 ↗581 human trials on ClinicalTrials.gov test Gabapentin — 369 completed, 37 recruiting now. See all on ClinicalTrials.gov ↗
- Kynurenic Acid and Serotonin as Perioperative Neuroinflammatory Biomarkers in Sequential Third Molar Surgery · Impacted Third Molar, Postoperative Pain · 2020
- Feasibility of Early Gabapentin as an Intervention for Neurorecovery · Spinal Cord Injuries · 2026
- Multimodal Analgesia Effect on Post Surgical Patient · Obesity, Morbid, Surgery · 2025
What government agencies say
Official records from US, Canadian and EU regulators, each linked to its source.
Not a scheduled substance, but the DEA lists Gabapentin as a drug of concern. DEA fact sheet ↗
The current US prescription label has no boxed warning.
24 recalls of products named for Gabapentin. Most recent:
- 2025-10-29 · Class II: Failed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity . record ↗
- 2025-07-09 · Class II: Defective container; blister packaging inadequately sealed. record ↗
- 2025-04-16 · Class II: CGMP Deviations record ↗
Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗
362,654 adverse-event reports mention Gabapentin. Most often reported:
- Drug ineffective · 29,635
- Fatigue · 25,140
- Nausea · 22,785
- Pain · 21,256
- Off label use · 19,830
- Diarrhoea · 18,156
Reports often involve several drugs and serious illness; a report doesn't prove the drug caused the problem, and these counts can't tell you how often it happens. Source query (openFDA) ↗
LiverTox rates Gabapentin C — a probable rare cause of liver injury (3–12 published cases). LiverTox entry ↗
NIH has funded 45 research projects with Gabapentin in the title, $34,709,226 in total (1988–2026). NIH RePORTER ↗
Plain-language guides from the US government: MedlinePlus: Gabapentin ↗
Dosage people report
Reported side effects
How often each side effect came up across all reports.
What users say
First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.
“I took Gabapentin today and I'm feeling calm like I used to... After 3 years I can finally feel normal... stomach issues disappeared and my sleep improved.”
“I’m prescribed gabapentin for anxiety but it stopped working. I was using it every other day for a long time and doing pretty good but then my sleep got all messed up.”
“I found that Neurontin is absolutely amazing for anxiety, social interaction and uplifting mood.”
“I'm about +5 hours after my 2g dose... I feel very upbeat... A functioning, mood-enhanced, relaxation with undertones of stimulation.”
Top discussions (5)
- How I reversed my epigenetic age by 10 years ↗
- The Hangover Effect: Feeling Great After Drinking Too Much ↗
- Most effective and profoundly noticeable substance for Social Anxiety ↗
- I accidentally cured my ADHD and I don’t know exactly why. Help. ↗
- Saffron is easy to grow. Not only does it come back every year by itself but it also multiplies giving you more saffron each year thereafter. It's a lovely purple flower so it is attractive to grow. ↗
Gabapentin compared
Other options for anxiety
Sources
- User reports: 145 mentions in public discussions, quoted with a link to each discussion (e.g. this thread ↗).
- PubMed (US National Library of Medicine, NIH): meta-analyses ↗ · randomized trials ↗
- ClinicalTrials.gov (NIH): registered trials ↗
- FDA drug label (DailyMed) ↗
- FDA adverse-event reports (FAERS) ↗
- FDA recalls ↗
- US DEA ↗
- LiverTox (NIH) ↗
- MedlinePlus (NIH) ↗
- NIH RePORTER ↗
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate